Positive performance of venture capital funding for European life sciences companies

In the third quarter of 2021, European life sciences companies raised a total of EUR 2.2bn in venture capital funding. Although the performance is almost the same as in the same quarter last year, the accumulated funding volume in 2021 increased by 65% compared to the first three quarters of 2020. In addition, the accumulated volume of 2021 already exceeds the total funding volume of 2020 by 23%.

In 2021 to date, the largest transaction has been the Series D venture funding of UK-based CMR Surgical in the amount of EUR 497m.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: